Enfortumab vedotin + Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Cancer
Conditions
Urothelial Cancer
Trial Timeline
Mar 30, 2020 → Mar 1, 2028
NCT ID
NCT04223856About Enfortumab vedotin + Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine
Enfortumab vedotin + Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine is a phase 3 stage product being developed by Astellas Pharma for Urothelial Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04223856. Target conditions include Urothelial Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04223856 | Phase 3 | Active |
Competing Products
20 competing products in Urothelial Cancer